How CSI supplied large quantities of ruxolitinib to a biotech’s ongoing Phase 3 oncology study involving 14 countries, nine depots and 67 site shipments Challenge CSI was approached by a biotech conducting a full global Phase 3 oncology study spanning 14 countries. We were asked to purchase and supply a significant quantity of ruxolitinib within a tight timeframe: with the contract signed in December 2022, the client aimed to have the first sites supplied by March 2023. The

Biopharmaceuticals have seen significant advances in recent years, particularly with the development of biologics and biosimilars. These innovative therapies have revolutionised the treatment landscape for various diseases, offering targeted and personalised approaches. Currently, 80% of the top-selling pharmaceuticals are biologics and, as the demand for these therapies continues to rise, the development of biosimilars has had a significant positive impact on costs for clini